Robert's Feed
Apr 30, 2015
via Breakingviews

Salesforce’s slow growth may prompt hunt for buyer

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Salesforce.com’s slowing growth makes this a good time to seek a suitor. The $47 billion software outfit is on the market, according to Bloomberg. Oracle and Microsoft are looking to beef up cloud computing operations, putting them in the forefront of possible buyers. Founder Marc Benioff has been offloading shares steadily, and persistent losses and disappointing revenue growth could tempt him to hawk the whole thing.

Apr 28, 2015
via Breakingviews

Huge Apple payouts play catch-up with China growth

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple can’t pay out its readies fast enough. The $760 billion iPhone-making money machine is adding $50 billion more to its buyback plans. Throw in an increased dividend, and the total set to go back to shareholders between 2012 and 2017 is an eye-watering $200 billion.

Apr 27, 2015
via Breakingviews

Pharma Arbageddon fears keep traders on sidelines

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Fear is keeping traders on the sidelines of the latest pharma mega-deals. Teva Pharmaceutical Industries is offering $40 billion for Mylan, which has put $33.5 billion on the table for Perrigo. These would usually be catnip for M&A punters. But recent failures have made them skittish. And these two hostile battles come with cross-border complexity, antitrust and a poison pill. No wonder arbs are wary.

Apr 27, 2015
via Breakingviews

Pharma Arbageddon fears keep traders on sidelines

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Fear is keeping traders on the sidelines of the latest pharma mega-deals. Teva Pharmaceutical Industries is offering $40 billion for Mylan, which has put $33.5 billion on the table for Perrigo. These would usually be catnip for M&A punters. But recent failures have made them skittish. And these two hostile battles come with cross-border complexity, antitrust and a poison pill. No wonder arbs are wary.

Apr 21, 2015
via Breakingviews

Teva’s $40 bln hostile bid puts hope over reality

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Teva Pharmaceutical Industries’ $40 billion hostile bid is putting hope over reality. The Israeli drugmaker needs a deal to shore up falling sales. Smaller rival Mylan offers that and oodles of synergies. A tie-up, though, would face antitrust concerns, require high leverage and have to get around a powerful poison pill. No wonder the market is skeptical.

Apr 15, 2015
via Breakingviews

EU’s competition sprawl as worrying as Google’s

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The European Union’s competition sprawl is as worrying as Google’s. Trustbusters on Wednesday accused the $360 billion web giant of favoring its own shopping search results – and broadened the case to include its Android mobile operating system. Investigations and appeals may take a decade. Brussels is going down the same treacherous path as ever-expanding Google.

Apr 15, 2015
via Breakingviews

EU’s competition sprawl as worrying as Google’s

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The European Union’s competition sprawl is as worrying as Google’s. Trustbusters on Wednesday accused the $360 billion web giant of favoring its own shopping search results – and broadened the case to include its Android mobile operating system. Investigations and appeals may take a decade. Brussels is going down the same treacherous path as ever-expanding Google.

Apr 6, 2015
via Breakingviews

Request for IBM activism likely falls on deaf ears

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Requests from some big unnamed shareholders for activism at IBM are likely to fall on deaf ears. No question investors in the company run by Ginni Rometty have reason to be dissatisfied. Big Blue’s top line has shrunk for 11 straight quarters. The IT giant’s shares have fallen about 25 percent from their high, and there’s no hint that the company has figured out a way to reverse course. The snag is that activists don’t have an obvious playbook for IBM’s recovery either.

Apr 6, 2015
via Breakingviews

Request for IBM activism likely falls on deaf ears

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Requests from some big unnamed shareholders for activism at IBM are likely to fall on deaf ears. No question investors in the company run by Ginni Rometty have reason to be dissatisfied. Big Blue’s top line has shrunk for 11 straight quarters. The IT giant’s shares have fallen about 25 percent from their high, and there’s no hint that the company has figured out a way to reverse course. The snag is that activists don’t have an obvious playbook for IBM’s recovery either.

Mar 30, 2015
via Breakingviews

$12.8 bln prescription may clear up pharmacy M&A

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

A $12.8 billion prescription may clear up pharmacy benefit managers’ chronic M&A. UnitedHealth Group is paying a 27 percent premium for drug middleman Catamaran and should generate more than enough savings to cover it. That might sound like a concoction others might want to try. But the buyer is playing catch-up. And its target is usually a buyer. Catamaran’s capitulation indicates benefit managers no longer need a dose of dealmaking.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert